United States Food and Drug Administration

"United States Food and Drug Administration" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An agency of the PUBLIC HEALTH SERVICE concerned with the overall planning, promoting, and administering of programs pertaining to maintaining standards of quality of foods, drugs, therapeutic devices, etc.

Descriptor ID	D014486
MeSH Number(s)	I01.409.418.750.600.650.760 N03.540.348.500.500.600.650.760
Concept/Terms	United States Food and Drug Administration United States Food and Drug Administration United States Food, Drug Administration USFDA Food and Drug Administration (U.S.) Food and Drug Administration

Below are MeSH descriptors whose meaning is more general than "United States Food and Drug Administration".

Anthropology, Education, Sociology and Social Phenomena [I]
Social Sciences [I01]
Government [I01.409]
Government Agencies [I01.409.418]
United States Government Agencies [I01.409.418.750]
United States Dept. of Health and Human Services [I01.409.418.750.600]
United States Public Health Service [I01.409.418.750.600.650]
United States Food and Drug Administration [I01.409.418.750.600.650.760]
Health Care [N]
Health Care Economics and Organizations [N03]
Organizations [N03.540]
Government [N03.540.348]
Federal Government [N03.540.348.500]
United States Government Agencies [N03.540.348.500.500]
United States Dept. of Health and Human Services [N03.540.348.500.500.600]
United States Public Health Service [N03.540.348.500.500.600.650]
United States Food and Drug Administration [N03.540.348.500.500.600.650.760]

Below are MeSH descriptors whose meaning is related to "United States Food and Drug Administration".

Below are MeSH descriptors whose meaning is more specific than "United States Food and Drug Administration".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "United States Food and Drug Administration" by people in this website by year, and whether "United States Food and Drug Administration" was a major or minor topic of these publications.

Bar chart showing 26 publications over 16 distinct years, with a maximum of 5 publications in 2021

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2005	0	1	1
2006	0	3	3
2008	0	1	1
2013	0	2	2
2014	1	1	2
2015	1	0	1
2016	0	1	1
2017	1	0	1
2018	0	2	2
2019	1	0	1
2020	0	1	1
2021	0	5	5
2022	0	2	2
2023	0	1	1
2024	0	1	1
2025	0	1	1

Below are the most recent publications written about "United States Food and Drug Administration" by people in Profiles.

Pressly MA, Schuck R, Mummaneni P, Roman YM, Pacanowski M. Utilization of polygenic risk scores in drug development protocols. Pharmacogenomics. 2025 Feb-Mar; 26(3-4):75-79.

View in: PubMed
Blumer V, Januzzi JL, Lindenfeld J, Solomon SD, Psotka MA, Carson PE, Bristow MR, Abraham WT, Gandotra C, Saville BR, O'Connor C, Fiuzat M. Heart?Failure Drug Development Over?the?Eras: From the Heart?Failure Collaboratory. JACC Heart Fail. 2024 Nov; 12(11):1803-1813.

View in: PubMed
Idris MY, Fitzsimmons WE, Pemu P. Quantifying Clinical Trial Diversity in Pivotal Registration Trials of FDA Novel Drug Approvals. Ther Innov Regul Sci. 2024 01; 58(1):175-183.

View in: PubMed
Kelsey MD, Patrick-Lake B, Abdulai R, Broedl UC, Brown A, Cohn E, Curtis LH, Komelasky C, Mbagwu M, Mensah GA, Mentz RJ, Nyaku A, Omokaro SO, Sewards J, Whitlock K, Zhang X, Bloomfield GS. Inclusion and diversity in clinical trials: Actionable steps to drive lasting change. Contemp Clin Trials. 2022 05; 116:106740.

View in: PubMed
Whitehouse P, Gandy S, Saini V, George DR, Larson EB, Alexander GC, Avorn J, Brownlee S, Camp C, Chertkow H, Fugh-Berman A, Howard R, Kesselheim A, Langa KM, Perry G, Richard E, Schneider L. Making the Case for Accelerated Withdrawal of Aducanumab. J Alzheimers Dis. 2022; 87(3):1003-1007.

View in: PubMed
Gandotra C, Clark J, Liu Q, Senatore FF, Rose M, Zhang J, Stockbridge NL. Heart Failure Population with Therapeutic Response to Sacubitril/Valsartan, Spironolactone and Candesartan: FDA Perspective. Ther Innov Regul Sci. 2022 01; 56(1):4-7.

View in: PubMed
Jones DM, Guy MC, Soule E, Sakuma KK, Pokhrel P, Orloff M, Trinidad D, Smith D, Browley S, Walker AP, Bullock S, Eissenberg T, Fagan P. Characterization of Electronic Cigarette Warning Statements Portrayed in YouTube Videos. Nicotine Tob Res. 2021 08 04; 23(8):1358-1366.

View in: PubMed
Gorantla S, Dabholkar N, Sharma S, Rapalli VK, Alexander A, Singhvi G. Chitosan-based microneedles as a potential platform for drug delivery through the skin: Trends and regulatory aspects. Int J Biol Macromol. 2021 Aug 01; 184:438-453.

View in: PubMed
Kerestes C, Delafield R, Elia J, Chong E, Kaneshiro B, Soon R. "It was close enough, but it wasn't close enough": A qualitative exploration of the impact of direct-to-patient telemedicine abortion on access to abortion care. Contraception. 2021 07; 104(1):67-72.

View in: PubMed
Hou W, Ding M, Li X, Zhou X, Zhu Q, Varela-Ramirez A, Yi C. Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials. J Cancer Res Clin Oncol. 2021 Aug; 147(8):2407-2420.

View in: PubMed

People

Explore

Similar Concepts

Top Journals